07 Oct LATEST NEWS: 4DMedical one of “Three Emerging Medical Device Companies” profiled by Switzer/NABtrade
James Dunn commentary:
“Imaging company 4DMedical (4DX) surged on to the ASX screens in its August 2020 float, with the shares, issued in the prospectus at 73 cents, opening for trade at $1.47. 4DX reached $2.60 in October 2020, but more than halved subsequently, plumbing $1.19 in May 2021.
4DMedical aims to disrupt the respiratory diagnostic imaging market with its unique four-dimensional lung imaging technology, XV Lung Ventilation Analysis Software (XV LVAS), which maps and measures lung motion and air flow by converting sequences of X-ray images into four-dimensional quantitative data. The 4Dx technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis and to monitor changes over time. At the heart of the process is a proprietary technique 4DMedical has developed, inspired by wind-tunnel technology, which combines fluoroscopy and advanced visualisation to generate high-resolution images of the motion of, and airflow through, lung tissue.
In May 2020, the XV LVAS technology received 510(k) clearance from the FDA, following a major confirmatory clinical trial of the XV Technology, conducted at Cedars-Sinai Hospital in Los Angeles, California. The clinical trial showed that XV gave clinicians much more detailed information than the commonly used pulmonary function test (PFT) and computed tomography (CT) imaging methods, confirming 4Dx’s belief that the unique and non-invasive XV technology enables unprecedented insight into pulmonary functioning, which is critical in the analysis and treatment of respiratory diseases.
The clinical trial demonstrated that XV not only matched the performance of current ‘gold-standard’ measures and other clinically available measures, but it was also more predictive than other measures in assessing the onset of conditions such as radiation-induced pneumonitis and/or pulmonary fibrosis.
In addition, the trial found that XV was clearly superior to the major incumbent testing technologies, PFT and CT, in detecting loss of regional lung function associated with early-stage disease progression, both in terms of sensitivity to structural changes in the lung (where it was compared to CT) and in standard lung function tests (where it was compared to PFT.) 4DMedical says XV is a break-through medical technology and a potentially world-changing advance in better and more timely diagnosis – and thus, improved treatment outcomes – for all lung disorders, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.
4DX has the technology in eight separate clinical trials, and three clinical pilot programs, in Australia and the US. Earlier this month it announced the successful completion of Phase One of a clinical pilot program with Australia’s leading medical imaging provider, I-MED Radiology Network (I-MED), whose radiologists have been using XV LVAS in patient settings, on respiratory diseases including asthma, COPD, bronchiectasis, sarcoidosis, silicosis and “long COVID.” The company says Phase One of the trial resulted in “overwhelmingly positive feedback from I-MED radiologists and patients.”
All prices and analysis at 6 October 2021. This information was produced by Switzer Financial Group Pty Ltd (ABN 24 112 294 649), which is an Australian Financial Services Licensee (Licence No. 286 531This material is intended to provide general advice only. It has been prepared without having regard to or taking into account any particular investor’s objectives, financial situation and/or needs. All investors should therefore consider the appropriateness of the advice, in light of their own objectives, financial situation and/or needs, before acting on the advice. This article does not reflect the views of WealthHub Securities Limited.”
Read the full article here: https://www.nabtrade.com.au/investor/insights/latest-news/news/2021/10/three_emerging_medic>